Cargando…
22. International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Outcome
BACKGROUND: Given the limited collaborative international studies that evaluated COVID-19 in patients with cancer in comparison to patients without cancer, we aimed to determine the independent risk factors associated with increased 30-day mortality and the impact of novel treatment modalities in a...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644395/ http://dx.doi.org/10.1093/ofid/ofab466.022 |
_version_ | 1784610075495628800 |
---|---|
author | Hachem, Ray Y Chaftari, Anne-Marie Masayuki, Nigo Hamerschlak, Nelson Dagher, Hiba Jiang, Ying Siddiqui, Bilal Bayle, Arnaud Somer, Robert Cruz, Ana Fernandez Gorak, Edward Bhinder, Arvinder Mori, Nobuyoshi Datoguia, Tarcila Shelanski, Samuel Dragvich, Tomislav Kiat, Yee Elise Vong Fakhreddine, Suha Hanna, Pierre Abi Chemaly, Roy F Mulanovich, Victor E Adachi, Javier Borjan, Jovan Khawaja, Fareed Granwehr, Bruno John, Teny Guevara, Eduardo Yepez Torres, Harrys A Slavin, Monica Teh, Benjamin Subbiah, Vivek Kontoyiannis, Dimitrios P Malek, Alexandre Raad, Issam I |
author_facet | Hachem, Ray Y Chaftari, Anne-Marie Masayuki, Nigo Hamerschlak, Nelson Dagher, Hiba Jiang, Ying Siddiqui, Bilal Bayle, Arnaud Somer, Robert Cruz, Ana Fernandez Gorak, Edward Bhinder, Arvinder Mori, Nobuyoshi Datoguia, Tarcila Shelanski, Samuel Dragvich, Tomislav Kiat, Yee Elise Vong Fakhreddine, Suha Hanna, Pierre Abi Chemaly, Roy F Mulanovich, Victor E Adachi, Javier Borjan, Jovan Khawaja, Fareed Granwehr, Bruno John, Teny Guevara, Eduardo Yepez Torres, Harrys A Slavin, Monica Teh, Benjamin Subbiah, Vivek Kontoyiannis, Dimitrios P Malek, Alexandre Raad, Issam I |
author_sort | Hachem, Ray Y |
collection | PubMed |
description | BACKGROUND: Given the limited collaborative international studies that evaluated COVID-19 in patients with cancer in comparison to patients without cancer, we aimed to determine the independent risk factors associated with increased 30-day mortality and the impact of novel treatment modalities in a large group of cancer and non-cancer patients with COVID-19 from multiple countries. METHODS: We retrospectively collected de-identified data on cancer and non-cancer patients diagnosed with COVID-19 between January and November 2020, at 16 centers in Asia, Australia, Europe, North America, and South America. A logistic regression model was used to identify independent predictors of all-cause mortality within 30 days after COVID-19 diagnosis. RESULTS: Of the total 4015 COVID-19 confirmed patients entered, we analyzed 3966 patients, 1115 cancer and 2851 non-cancer patients. Cancer patients were older than non-cancer patients (median age, 61 vs 50 years; p< 0.0001); more likely to be pancytopenic , had pulmonary disorders, hypertension, diabetes mellitus. In addition, they were more likely to present with higher inflammatory biomarkers (D-dimer, ferritin and procalcitonin), but were less likely to present with clinical symptoms. By multivariable logistic regression analysis, cancer was an independent risk factor for 30-day mortality (OR 1.46; 95% CI 1.03 to 2.07; p=0.035). Older age (≥65 years) was the strongest predictor of 30-day mortality in all patients (OR 4.55; 95% CI 3.34 to 6.20; p< 0.0001). Remdesivir was the only therapeutic agent independently associated with decreased 30-day mortality (OR 0.58; CI 0.39-0.88; p=0.009). Among patients on low-flow oxygen at admission, patients who received remdesivir had a lower 30-day mortality rate than those who were on high flow oxygen (5.9% vs 17.6%; p=0.03). Patients transfused with convalescent plasma within 1 day of diagnosis had a lower 30-day mortality rate than those transfused later (1% vs 7%, p=0.04). CONCLUSION: Cancer is an independent risk factor for increased 30-day all-cause mortality from COVID-19. Remdesivir, particularly in patients receiving low-flow oxygen, can reduce 30-day all-cause mortality, as well as convalescent plasma given early after COVID-19 diagnosis. DISCLOSURES: Roy F. Chemaly, MD, MPH, FACP, FIDSA, AiCuris (Grant/Research Support)Ansun Biopharma (Consultant, Grant/Research Support)Chimerix (Consultant, Grant/Research Support)Clinigen (Consultant)Genentech (Consultant, Grant/Research Support)Janssen (Consultant, Grant/Research Support)Karius (Grant/Research Support)Merck (Consultant, Grant/Research Support)Molecular Partners (Consultant, Advisor or Review Panel member)Novartis (Grant/Research Support)Oxford Immunotec (Consultant, Grant/Research Support)Partner Therapeutics (Consultant)Pulmotec (Consultant, Grant/Research Support)Shire/Takeda (Consultant, Grant/Research Support)Viracor (Grant/Research Support)Xenex (Grant/Research Support) Fareed Khawaja, MBBS, Eurofins Viracor (Research Grant or Support) Monica Slavin, MBBS,MD, F2G (Advisor or Review Panel member)Merck (Advisor or Review Panel member)Pfizer (Advisor or Review Panel member) Dimitrios P. Kontoyiannis, MD, Astellas (Consultant)Cidara Therapeutics (Advisor or Review Panel member)Gilead Sciences (Consultant, Grant/Research Support, Other Financial or Material Support, Honoraria) |
format | Online Article Text |
id | pubmed-8644395 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-86443952021-12-06 22. International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Outcome Hachem, Ray Y Chaftari, Anne-Marie Masayuki, Nigo Hamerschlak, Nelson Dagher, Hiba Jiang, Ying Siddiqui, Bilal Bayle, Arnaud Somer, Robert Cruz, Ana Fernandez Gorak, Edward Bhinder, Arvinder Mori, Nobuyoshi Datoguia, Tarcila Shelanski, Samuel Dragvich, Tomislav Kiat, Yee Elise Vong Fakhreddine, Suha Hanna, Pierre Abi Chemaly, Roy F Mulanovich, Victor E Adachi, Javier Borjan, Jovan Khawaja, Fareed Granwehr, Bruno John, Teny Guevara, Eduardo Yepez Torres, Harrys A Slavin, Monica Teh, Benjamin Subbiah, Vivek Kontoyiannis, Dimitrios P Malek, Alexandre Raad, Issam I Open Forum Infect Dis Oral Abstracts BACKGROUND: Given the limited collaborative international studies that evaluated COVID-19 in patients with cancer in comparison to patients without cancer, we aimed to determine the independent risk factors associated with increased 30-day mortality and the impact of novel treatment modalities in a large group of cancer and non-cancer patients with COVID-19 from multiple countries. METHODS: We retrospectively collected de-identified data on cancer and non-cancer patients diagnosed with COVID-19 between January and November 2020, at 16 centers in Asia, Australia, Europe, North America, and South America. A logistic regression model was used to identify independent predictors of all-cause mortality within 30 days after COVID-19 diagnosis. RESULTS: Of the total 4015 COVID-19 confirmed patients entered, we analyzed 3966 patients, 1115 cancer and 2851 non-cancer patients. Cancer patients were older than non-cancer patients (median age, 61 vs 50 years; p< 0.0001); more likely to be pancytopenic , had pulmonary disorders, hypertension, diabetes mellitus. In addition, they were more likely to present with higher inflammatory biomarkers (D-dimer, ferritin and procalcitonin), but were less likely to present with clinical symptoms. By multivariable logistic regression analysis, cancer was an independent risk factor for 30-day mortality (OR 1.46; 95% CI 1.03 to 2.07; p=0.035). Older age (≥65 years) was the strongest predictor of 30-day mortality in all patients (OR 4.55; 95% CI 3.34 to 6.20; p< 0.0001). Remdesivir was the only therapeutic agent independently associated with decreased 30-day mortality (OR 0.58; CI 0.39-0.88; p=0.009). Among patients on low-flow oxygen at admission, patients who received remdesivir had a lower 30-day mortality rate than those who were on high flow oxygen (5.9% vs 17.6%; p=0.03). Patients transfused with convalescent plasma within 1 day of diagnosis had a lower 30-day mortality rate than those transfused later (1% vs 7%, p=0.04). CONCLUSION: Cancer is an independent risk factor for increased 30-day all-cause mortality from COVID-19. Remdesivir, particularly in patients receiving low-flow oxygen, can reduce 30-day all-cause mortality, as well as convalescent plasma given early after COVID-19 diagnosis. DISCLOSURES: Roy F. Chemaly, MD, MPH, FACP, FIDSA, AiCuris (Grant/Research Support)Ansun Biopharma (Consultant, Grant/Research Support)Chimerix (Consultant, Grant/Research Support)Clinigen (Consultant)Genentech (Consultant, Grant/Research Support)Janssen (Consultant, Grant/Research Support)Karius (Grant/Research Support)Merck (Consultant, Grant/Research Support)Molecular Partners (Consultant, Advisor or Review Panel member)Novartis (Grant/Research Support)Oxford Immunotec (Consultant, Grant/Research Support)Partner Therapeutics (Consultant)Pulmotec (Consultant, Grant/Research Support)Shire/Takeda (Consultant, Grant/Research Support)Viracor (Grant/Research Support)Xenex (Grant/Research Support) Fareed Khawaja, MBBS, Eurofins Viracor (Research Grant or Support) Monica Slavin, MBBS,MD, F2G (Advisor or Review Panel member)Merck (Advisor or Review Panel member)Pfizer (Advisor or Review Panel member) Dimitrios P. Kontoyiannis, MD, Astellas (Consultant)Cidara Therapeutics (Advisor or Review Panel member)Gilead Sciences (Consultant, Grant/Research Support, Other Financial or Material Support, Honoraria) Oxford University Press 2021-12-04 /pmc/articles/PMC8644395/ http://dx.doi.org/10.1093/ofid/ofab466.022 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Oral Abstracts Hachem, Ray Y Chaftari, Anne-Marie Masayuki, Nigo Hamerschlak, Nelson Dagher, Hiba Jiang, Ying Siddiqui, Bilal Bayle, Arnaud Somer, Robert Cruz, Ana Fernandez Gorak, Edward Bhinder, Arvinder Mori, Nobuyoshi Datoguia, Tarcila Shelanski, Samuel Dragvich, Tomislav Kiat, Yee Elise Vong Fakhreddine, Suha Hanna, Pierre Abi Chemaly, Roy F Mulanovich, Victor E Adachi, Javier Borjan, Jovan Khawaja, Fareed Granwehr, Bruno John, Teny Guevara, Eduardo Yepez Torres, Harrys A Slavin, Monica Teh, Benjamin Subbiah, Vivek Kontoyiannis, Dimitrios P Malek, Alexandre Raad, Issam I 22. International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Outcome |
title | 22. International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Outcome |
title_full | 22. International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Outcome |
title_fullStr | 22. International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Outcome |
title_full_unstemmed | 22. International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Outcome |
title_short | 22. International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Outcome |
title_sort | 22. international multicenter study comparing cancer to non-cancer patients with covid-19: impact of risk factors and treatment modalities on outcome |
topic | Oral Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644395/ http://dx.doi.org/10.1093/ofid/ofab466.022 |
work_keys_str_mv | AT hachemrayy 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT chaftariannemarie 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT masayukinigo 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT hamerschlaknelson 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT dagherhiba 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT jiangying 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT siddiquibilal 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT baylearnaud 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT somerrobert 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT cruzanafernandez 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT gorakedward 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT bhinderarvinder 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT morinobuyoshi 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT datoguiatarcila 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT shelanskisamuel 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT dragvichtomislav 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT kiatyeeelisevong 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT fakhreddinesuha 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT hannapierreabi 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT chemalyroyf 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT mulanovichvictore 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT adachijavier 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT borjanjovan 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT khawajafareed 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT granwehrbruno 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT johnteny 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT guevaraeduardoyepez 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT torresharrysa 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT slavinmonica 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT tehbenjamin 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT subbiahvivek 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT kontoyiannisdimitriosp 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT malekalexandre 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome AT raadissami 22internationalmulticenterstudycomparingcancertononcancerpatientswithcovid19impactofriskfactorsandtreatmentmodalitiesonoutcome |